Cancer Cells Acquire Mitotic Drug Resistance Properties Through Beta I-Tubulin Mutations and Alterations in the Expression of Beta-Tubulin Isotypes

• Chun Hei Antonio Cheung,

  Affiliation National Institute of Cancer Research, National Health Research Institutes (NHRI), Tainan, Taiwan, Republic of China

  ⨯
• Su-Ying Wu,

  Affiliation Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes (NHRI), Zhunan, Taiwan, Republic of China

  ⨯
• Tian-Ren Lee,

  Affiliation National Institute of Cancer Research, National Health Research Institutes (NHRI), Tainan, Taiwan, Republic of China

  ⨯
• Chi-Yen Chang,

  Affiliation National Institute of Cancer Research, National Health Research Institutes (NHRI), Tainan, Taiwan, Republic of China

  ⨯
• Jian-Sung Wu,

  Affiliation Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes (NHRI), Zhunan, Taiwan, Republic of China

  ⨯
• Hsing-Pang Hsieh,

  Affiliation Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes (NHRI), Zhunan, Taiwan, Republic of China

  ⨯
• Jang-Yang Chang

  * E-mail: jychang@nhri.org.tw

  Affiliations National Institute of Cancer Research, National Health Research Institutes (NHRI), Tainan, Taiwan, Republic of China, Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, Republic of China

  ⨯